Abstract
Purpose
This study aims to determine whether a low dose of the gonadotropin releasing hormone antagonist, cetrorelix, prevents a premature luteinizing hormone (LH) surge and affects in vitro fertilization (IVF) outcomes compared to the standard dose of 0.25 mg/day.
Methods
In this study, 45 IVF/intracytoplasmic sperm injection patients were stimulated with recombinant follicle stimulation hormone from day 2 of the cycle. Cetrorelix was injected daily from day 6 of gonadotropin administration. Twenty-two patients received cetrorelix at a dose of 0.25 mg/day, whereas 23 participants received half dose.
Results
The mean consumption of gonadotropins was significantly higher in patients receiving 0.25 mg/day of cetrorelix (2,213 vs. 1,350 U; p = 0.046). The clinical pregnancy rates were similar in both groups (31.8 vs. 47.8 %; p = 0.273). Premature LH surge was detected in 9.1 % of the patients receiving cetrorelix 0.25 mg/day and in 13 % of the patients receiving cetrorelix 0.125 mg/day (p > 0.05). The difference between two groups was not statistically significant (p > 0.05).
Conclusıons
Our results suggest that there is no difference between a cetrorelix dose of 0.125 or 0.25 mg/day in preventing premature LH rise during ovarian stimulation for IVF.
Similar content being viewed by others
References
Porter RN, Smith W, Craft IL et al (1984) Induction of ovulation for in vitro fertilization using buserelin and gonadotropins. Lancet 2:1284–1285
Al-Inany H, Wahba A, Peitsidis P (2011) Changing attitudes in ovarian stimulation. Womens Health 7(5):505–5077
Olivennes F, Alfarez S, Bouchard P et al (1998) The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 13:2411–2414
Albano C, Smitz J, Camus M et al (1997) Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 67:917–922
Al-Inany H, Aboulghar M (2001) Gonadotrophin–releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 4:CD001750
Al-Inany HG, Youssef MA, Aboulghar M et al (2011) GnRH antagonists are safer than agonists: an update of a Cochrane review. Hum Reprod Update 17(4):435
Tzeng CR, Chen HJ, Lin YH et al (2008) Effect of a lower-dose cetrorelix acetate protocol on in vitro fertilization outcome. Int J Gynaecol Obstet 100(3):271–274
Chen HJ, Lin YH, Hsieh BC et al (2006) Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation? J Assist Reprod Genet 23(6):289–292
Tiboni GM, Palumbo P, Leonzio E et al (2011) Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation. Gynecol Endocrinol 27(11):885–889
Olivennes F, Belaisch-Allart J, Emperaire JC et al (2000) Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Hum Reprod 73:314–320
Al-Inany HG, Abou-Setta AM, Aboulghar M (2006) Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 3:1750
Hernandez ER (2000) Embryo implantation and GnRH antagonists. Embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 15:1211–1216
Felberbaum R, Reissmann T, Kupker W et al (1996) Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages. J Asist Reprod Genet 13:216–222
Nikolettos N, Al-Hasani S, Felberbaum R et al (2000) Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists. Eur J Obstet Gynecol Reprod Biol 93(1):91–95
Seelig AS, Al-Hasani S, Katalinic A et al (2002) Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 77(3):472–475
Engel JB, Ludwig M, Junge K et al (2003) No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols. Reprod Biomed Online 6:482–487
Conflict of interest
The authors report no declarations of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kerimoğlu, Ö.S., Ercan, C.M., Keskin, U. et al. Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes. Arch Gynecol Obstet 288, 691–695 (2013). https://doi.org/10.1007/s00404-013-2806-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-013-2806-z